Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APH-1501-5 is a nanoparticle-encapsulated formulation of cannabidiol (CBD) developed by Aphios for the treatment of prostate cancer. Utilizing Aphios's proprietary Polymer and Liposomal Nanospheres (PNS) technology, the drug is designed to enhance the solubility, stability, and bioavailability of CBD, which is otherwise highly lipophilic and poorly absorbed. In the context of prostate cancer, CBD is investigated for its ability to inhibit tumor growth, induce apoptosis, and reduce cell migration and invasion. These effects are thought to be mediated through interactions with cannabinoid receptors (CB1 and CB2), GPR55, and various transient receptor potential (TRP) channels, as well as through the modulation of intracellular signaling pathways such as PI3K/Akt and ERK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on APH-1501-5.